Implementation of a Randomized Controlled Trial to Improve Treatment with Oral Anticoagulants in Patients with Atrial Fibrillation (IMPACT-AFib)

Project Title Implementation of a Randomized Controlled Trial to Improve Treatment with Oral Anticoagulants in Patients with Atrial Fibrillation (IMPACT-AFib)
Date Posted
Tuesday, May 7, 2019
Status
In progress
Deliverables
Description

An individually randomized trial of a patient and provider level educational intervention to increase anticoagulant use among untreated members with atrial fibrillation and increased risk of stroke (i.e. CHA2DS2-VASc score ≥2). This project is a proof of concept effort, the first trial conducted using Sentinel Infrastructure, and will inform future interventional studies that are designed to utilize existing healthcare data as part of their design.

The Sentinel Operations Center posted a draft protocol for public comment on March 1, 2017 through March 15, 2017. Revised versions were approved by FDA on October 2, 2017, November 24, 2017, April 19, 2018, February 27, 2019. The latter was approved for implementation by BRANY IRB on March 19, 2019. A log of changes is included in the revised protocol (v5.0).

The statistical analysis plan was approved by both entities in February 2019.

Workgroup Leader(s)

Richard Platt, MD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

Christopher Granger, MD; Sean Pokorney, MD, MBA; Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, NC

Workgroup Members

Jacqueline Corrigan-Curay, MD, JD; Dianne Paraoan, MPH, BSN; Office of Medical Policy, Center for Drug Evaluation and Research, FDA, Silver Spring, MD

Hussein Al-Khalidi, PhD; Shuang Li, MS; Duke Clinical Research Institute and Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC

Sana Al-Khatib, MD, MHS; Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, NC

Sara Calvert, PharmD; Duke Clinical Research Institute and Clinical Trials Transformation Initiative, Duke University Medical Center, Durham, NC

Noelle Cocoros, DSc, MPH; Meighan Rogers Driscoll, MPH; Robert Jin, MS; Andrew Petrone, MPH; Jennifer Noble; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

Kevin Haynes, PharmD, MSCE; Lauren Parlett, PhD; HealthCore, Inc., Alexandria, VA

Cheryl Walraven, PhD; Annemarie Kline, MS, CHES; Daniel Knecht, MD, MBA; Aetna, a CVS Health company, Blue Bell, PA

Vinit Nair, BPharm, MS, RPh; Thomas Harkins, MPH, MA; Yunping Zhou, MS; Humana Healthcare Research Inc., Louisville, KY

Nancy Lin, ScD; OptumInsight Life Sciences Inc., Boston, MA

Debbe McCall, BS, MBA; Rowan Tree Perspectives Consulting, Murrieta, CA

Medical Product
anticoagulant
Health Outcome
atrial fibrillation
Population / Cohort
Patients with atrial fibrillation
Time Period
May 2017 – December 2021
Related Links
Scroll to Top